Page 371 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
PIVOT, US 146 Biopsy proven T1- Office visit & PSA every 6 mo Discouraged treatment for NR
[18783735] T2/Nx/M0 Bone scan every 5 yr asymptomatic progression
prostate cancer (e.g., per PSA)
1994-2002 of any
histological
grade,
diagnosed
within 12 mo,
PSA≤50
ng/mL, ≤75 yr,
bone scan
negative for
metastatic
disease,
estimated life
expectancy >10
yr, medically
and surgically fit
for RP

C-103